HBK Sorce Advisory LLC Boosts Position in AbbVie Inc. $ABBV

HBK Sorce Advisory LLC raised its position in AbbVie Inc. (NYSE:ABBV) by 41.7% during the 3rd quarter, Holdings Channel reports. The firm owned 29,745 shares of the company’s stock after acquiring an additional 8,750 shares during the quarter. HBK Sorce Advisory LLC’s holdings in AbbVie were worth $6,878,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Hobart Private Capital LLC grew its stake in AbbVie by 4.4% in the 3rd quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock valued at $261,000 after acquiring an additional 48 shares during the last quarter. Rise Advisors LLC lifted its holdings in shares of AbbVie by 3.4% in the third quarter. Rise Advisors LLC now owns 1,451 shares of the company’s stock valued at $336,000 after purchasing an additional 48 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of AbbVie by 1.1% in the second quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company’s stock valued at $848,000 after purchasing an additional 51 shares in the last quarter. FF Advisors LLC grew its position in shares of AbbVie by 3.6% in the second quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock valued at $286,000 after purchasing an additional 53 shares during the last quarter. Finally, Landaas & Co. WI ADV raised its position in shares of AbbVie by 1.1% during the 2nd quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock worth $920,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.4%

Shares of NYSE:ABBV opened at $227.82 on Tuesday. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The firm has a market cap of $402.64 billion, a price-to-earnings ratio of 172.59, a PEG ratio of 1.29 and a beta of 0.36. The stock’s 50-day moving average price is $226.58 and its two-hundred day moving average price is $211.60. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the company posted $3.00 EPS. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ABBV shares. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Bank of America lifted their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a report on Tuesday, November 4th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.